Cargando…

Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment

BACKGROUND/AIMS: Pancreatic ductal adenocarcinoma (PDA) is associated with an extremely poor prognosis. This study assessed the genetic diversity among patients with PDA and compared their mutational profiles before and after treatment. METHODS: Tumors and matched blood samples were obtained from 22...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Kyong-Ah, Woo, Sang Myung, Kim, Yun-Hee, Kong, Sun-Young, Lee, Min Kyoung, Han, Sung-Sik, Kim, Tae Hyun, Lee, Woo Jin, Park, Sang-Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860036/ https://www.ncbi.nlm.nih.gov/pubmed/30970447 http://dx.doi.org/10.5009/gnl18355

Ejemplares similares

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer
por: Yoon, Kyong-Ah, et al.
Publicado: (2018)

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
por: Woo, Sang Myung, et al.
Publicado: (2017)

Changes in Dietary Intake, Body Weight, Nutritional Status, and Metabolic Rate in a Pancreatic Cancer Patient
por: Kim, So Young, et al.
Publicado: (2013)

Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study
por: Woo, Sang Myung, et al.
Publicado: (2021)

Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer
por: Kim, Tae Hyun, et al.
Publicado: (2018)

Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer
por: Oh, Eun Sang, et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer
por: Kim, Juwan, et al.
Publicado: (2022)

Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer
por: Sohn, Seo Young, et al.
Publicado: (2018)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?
por: Nitsche, Ulrich, et al.
Publicado: (2016)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study
por: Woo, Sang Myung, et al.
Publicado: (2013)

Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer
por: Kim, Tae Hyun, et al.
Publicado: (2020)

Platelet-rich plasma treatment in patients with refractory thin endometrium and recurrent implantation failure: A comprehensive review
por: Kim, Min Kyoung, et al.
Publicado: (2022)

Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance
por: Kim, Hyo Suk, et al.
Publicado: (2023)

Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples
por: Choi, Sun Il, et al.
Publicado: (2019)

Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy
por: Joo, Jung Il, et al.
Publicado: (2021)

Laparoscopic radical distal pancreatosplenectomy with celiac axis excision following neoadjuvant chemotherapy for locally advanced pancreatic cancer
por: Kim, Yeon Su, et al.
Publicado: (2022)

Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center
por: Lee, Yong Jae, et al.
Publicado: (2018)

DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study
por: Woo, Sang Myung, et al.
Publicado: (2017)

Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer
por: Shin, Jung Kyong, et al.
Publicado: (2022)

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
por: Choi, Yoo Jin, et al.
Publicado: (2021)

Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare
por: Lee, Jun Hwa, et al.
Publicado: (2018)

Diagnostic model for pancreatic cancer using a multi-biomarker panel
por: Choi, Yoo Jin, et al.
Publicado: (2021)

Early prediction of neoadjuvant chemotherapy response for advanced breast cancer using PET/MRI image deep learning
por: Choi, Joon Ho, et al.
Publicado: (2020)

Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer
por: Paik, Woo Hyun, et al.
Publicado: (2015)

Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
por: Lee, Kyung-Hun, et al.
Publicado: (2012)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
por: Yoon, Min Sung, et al.
Publicado: (2022)

Development and Validation of a Prediction Model to Estimate Individual Risk of Pancreatic Cancer
por: Yu, Ami, et al.
Publicado: (2016)

Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel
por: Park, Jiyoung, et al.
Publicado: (2017)

Effect of Early Management on Pain and Depression in Patients with Pancreatobiliary Cancer: A Randomized Clinical Trial
por: Woo, Sang Myung, et al.
Publicado: (2019)

Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
por: Lee, Jong-chan, et al.
Publicado: (2016)

Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
por: Hong, Jung Yong, et al.
Publicado: (2021)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement
por: Lee, Jin Ho, et al.
Publicado: (2015)

Clinicopathological Aspects of 542 Cases of Pancreatic Cancer: a Special Emphasis on Small Pancreatic Cancer
por: Jung, Kee Wook, et al.
Publicado: (2007)

Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer
por: Kwak, Yoo-Kang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cdk9u9d0n0p8tp4oiucpgn2op5